ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO938

Seroresponse to Additional Doses of SARS-CoV-2 Vaccine Among Maintenance Dialysis Patients Over 6 Months

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Hsu, Caroline M., Tufts Medical Center, Boston, Massachusetts, United States
  • Lacson, Eduardo K., Tufts Medical Center, Boston, Massachusetts, United States
  • Manley, Harold J., Dialysis Clinic Inc, Nashville, Tennessee, United States
  • Aweh, Gideon N., Dialysis Clinic Inc, Nashville, Tennessee, United States
  • Johnson, Doug, Dialysis Clinic Inc, Nashville, Tennessee, United States
  • Weiner, Daniel E., Tufts Medical Center, Boston, Massachusetts, United States
Background

Among patients receiving maintenance dialysis, seroresponse to an initial vaccine series wanes over time. Previously, we showed that additional doses elicit a substantial short-term increase in seroresponse. Here, we assess seroresponse over time in a national sample of maintenance dialysis patients.

Methods

Using retrospective clinical data, we assessed seroresponse to additional SARS-CoV-2 vaccine doses over time among maintenance dialysis patients cared for at Dialysis Clinic, Inc (DCI) facilities. Via a clinical protocol available to dialysis providers, antibodies against SARS-CoV-2 spike antigen were assessed monthly alongside routine labwork. Patients with history of COVID-19 prior to additional dose and patients who received Janssen vaccine as an additional dose were excluded. Titers after a second additional dose (i.e., for most, a fourth dose) or after COVID-19 diagnosis were excluded from analysis.

Results

Among 1707 patients who had received an additional vaccine dose and had at least one titer level measured after the additional dose, more than 75% had a titer level at the upper limit of the assay in the first month after the additional dose. Titer levels then waned across vaccine types. By Month 6, median [IQR] titer was 68.37 [22.30, ≥100] among Moderna recipients, 59.94 [39.90, 79.97] among Moderna half-dose recipients, and 71.29 [22.46, ≥100] among Pfizer recipients.

Conclusion

Among patients receiving maintenance dialysis, anti-spike IgG levels after an additional SARS-CoV-2 vaccine dose wane over time across vaccine types. These results suggest a role for routine antibody monitoring to assess possible need for further re-dosing.

Funding

  • Private Foundation Support